L'Oreal CEO Nicolas Hieronimus stated that the rise in GLP-1 weight loss drugs is "a very important phenomenon" impacting beauty and skin care consumption. The company is designing products through brands like SkinCeuticals and Kiehl's to target side effects of rapid weight loss, such as loose skin. L'Oreal also increased its stake in dermatology firm Galderma to 20% last December, with both companies testing products on GLP-1 users.